CD147 is an MMP-inducing protein often implicated in cancer progression. The purpose of this study was to investigate the expression of CD147 in prostate cancer (PCa) progression and the prognostic ability of CD147 in predicting biochemical recurrence after prostatectomy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Plasma membrane-localized CD147 protein expression was quantified in patient samples using immunohistochemistry and multispectral imaging, and expression was compared to clinico-pathological features (pathologic stage, Gleason score, tumor volume, preoperative PSA, lymph node status, surgical margins, biochemical recurrence status) CD147 specificity and expression were confirmed with immunoblotting of prostate cell lines, and CD147 mRNA expression was evaluated in public expression microarray datasets of patient prostate tumors
Expression of CD147 protein was significantly decreased in localized tumors (pT2; p = 0 02) and aggressive PCa (≥pT3; p = 0 004), and metastases (p = 0 001) compared to benign prostatic tissue Decreased CD147 was associated with advanced pathologic stage (p = 0 009) and high Gleason score (p = 0 02), and low CD147 expression predicted biochemical recurrence (HR 0 55; 95 % CI 0 31-0 97; p = 0 04) independent of clinico-pathologic features Immunoblot bands were detected at 44 kDa and 66 kDa, representing non-glycosylated and glycosylated forms of CD147 protein, and CD147 expression was lower in tumorigenic T10 cells than non-tumorigenic BPH-1 cells (p = 0 02) Decreased CD147 mRNA expression was associated with increased Gleason score and pathologic stage in patient tumors but is not associated with recurrence status
Membrane-associated CD147 expression is significantly decreased in PCa compared to non-malignant prostate tissue and is associated with tumor progression, and low CD147 expression predicts biochemical recurrence after prostatectomy independent of pathologic stage, Gleason score, lymph node status, surgical margins, and tumor volume in multivariable analysis
BMC cancer 2015 Jul 25*** epublish ***
Tyler M Bauman, Jonathan A Ewald, Wei Huang, William A Ricke
Departments of Urology ,Carbone Cancer Center, University of Wisconsin, 7107 Wisconsin Institutes of Medical Research (WIMR), 1111 Highland Ave , 53705, Madison, WI, USA baumant@wusm wustl edu , Departments of Urology ,Carbone Cancer Center, University of Wisconsin, 7107 Wisconsin Institutes of Medical Research (WIMR), 1111 Highland Ave , 53705, Madison, WI, USA ewald@urology wisc edu , Departments of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA WHuang@uwhealth org , Departments of Urology ,Carbone Cancer Center, University of Wisconsin, 7107 Wisconsin Institutes of Medical Research (WIMR), 1111 Highland Ave , 53705, Madison, WI, USA